Heterologous HIV-based lentiviral/adenoviral vectors immunizations result in enhanced HIV-specific immunity

Vaccine

Volumn 28, Issue 20, 2010, Pages 3617-3624

  Asefa, Benyam ^a   Korokhov, Nikolay ^a   Lemiale, Franck ^a  

^a VIRxSYS Corporation   (United States)

Author keywords

Adenovirus; Heterologous immunization; HIV; Lentiviral vectors; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LENTIVIRUS VECTOR; NEUTRALIZING ANTIBODY; POL PROTEIN; REV PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; POPULATION; PRIORITY JOURNAL; SEROPREVALENCE;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION, SECONDARY; LENTIVIRUS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS;

EID: 77950596031     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.12.047     Document Type: Article

References (43)

1. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., and Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68 September (9) (1994) 6103-6110
2. Tindall B., and Cooper D.A. Primary HIV infection: host responses and intervention strategies. AIDS 5 January (1) (1991) 1-14
3. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68 July (7) (1994) 4650-4655
4. Pantaleo G., Demarest J.F., Soudeyns H., Graziosi C., Denis F., Adelsberger J.W., et al. Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature 370 August (6489) (1994) 463-467
5. Ferbas J., Kaplan A.H., Hausner M.A., Hultin L.E., Matud J.L., Liu Z., et al. Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8+ lymphocyte activity. J Infect Dis 172 August (2) (1995) 329-339
6. Yu S., Feng X., Shu T., Matano T., Hasegawa M., Wang X., et al. Potent specific immune responses induced by prime-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B. Vaccine 26 November (48) (2008) 6124-6131
7. Robinson H.L. HIV/AIDS vaccines: 2007. Clin Pharmacol Ther 82 December (6) (2007) 686-693
8. Cohen J. AIDS research. Did Merck's failed HIV vaccine cause harm?. Science 318 November (5853) (2007) 1048-1049
9. Cox K.S., Clair J.H., Prokop M.T., Sykes K.J., Dubey S.A., Shiver J.W., et al. DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles. J Virol 82 August (16) (2008) 8161-8171
10. Ledford H. HIV vaccine may raise risk. Nature 450 November (7168) (2007) 325
11. Liu J., O'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457 Jan (7225) (2009) 87-91
12. Lemiale F., Haddada H., Nabel G.J., Brough D.E., King C.R., and Gall J.G. Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine 25 March (11) (2007) 2074-2084
13. Sekaly R.P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?. J Exp Med 205 January (1) (2008) 7-12
14. Lemiale F., and Korokhov N. Lentiviral vectors for HIV disease prevention and treatment. Vaccine 28 (2009) 1949-1958
15. Blomer U., Naldini L., Kafri T., Trono D., Verma I.M., and Gage F.H. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol 71 September (9) (1997) 6641-6649
16. Kafri T., Blomer U., Peterson D.A., Gage F.H., and Verma I.M. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 17 November (3) (1997) 314-317
17. Lundstrom K. Latest development in viral vectors for gene therapy. Trends Biotechnol 21 March (3) (2003) 117-122
18. Cockrell A.S., and Kafri T. Gene delivery by lentivirus vectors. Mol Biotechnol 36 July (3) (2007) 184-204
19. Yee J.K., Friedmann T., and Burns J.C. Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol 43 Pt A (1994) 99-112
20. Lemiale F, Asefa B, Ye D, Chen C, Korokhov N, Humeau L. An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization. Vaccine 2009; doi:10.1016/j.vaccine.2009.10.089.
21. Lu X., Humeau L., Slepushkin V., Binder G., Yu Q., Slepushkina T., et al. Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol. J Gene Med 6 September (9) (2004) 963-973
22. Lu X., Yu Q., Binder G.K., Chen Z., Slepushkina T., Rossi J., et al. Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance. J Virol 78 July (13) (2004) 7079-7088
23. Levine B.L., Humeau L.M., Boyer J., MacGregor R.R., Rebello T., Lu X., et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 103 November (46) (2006) 17372-17377
24. Huang Y., Kong W.P., and Nabel G.J. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J Virol 75 May (10) (2001) 4947-4951
25. Kong W.P., Huang Y., Yang Z.Y., Chakrabarti B.K., Moodie Z., and Nabel G.J. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol 77 December (23) (2003) 12764-12772
26. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77 June (11) (2003) 6305-6313
27. Yang Z.Y., Wyatt L.S., Kong W.P., Moodie Z., Moss B., and Nabel G.J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 77 January (1) (2003) 799-803
28. Liu J., Ewald B.A., Lynch D.M., Denholtz M., Abbink P., Lemckert A.A., et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol 82 May (10) (2008) 4844-4852
29. Heemskerk B., Veltrop-Duits L.A., van Vreeswijk T., ten Dam M.M., Heidt S., Toes R.E., et al. Extensive cross-reactivity of CD4+ adenovirus-specific T cells: implications for immunotherapy and gene therapy. J Virol 77 June (11) (2003) 6562-6566
30. Olive M., Eisenlohr L., Flomenberg N., Hsu S., and Flomenberg P. The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope. Hum Gene Ther 13 July (10) (2002) 1167-1178
31. Almeida J.R., Price D.A., Papagno L., Arkoub Z.A., Sauce D., Bornstein E., et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204 October (10) (2007) 2473-2485
32. Turk G., Gherardi M.M., Laufer N., Saracco M., Luzzi R., Cox J.H., et al. Magnitude, breadth, and functional profile of T-cell responses during human immunodeficiency virus primary infection with B and BF viral variants. J Virol 82 March (6) (2008) 2853-2866
33. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107 June (12) (2006) 4781-4789
34. He Y., Zhang J., Donahue C., and Falo Jr. L.D. Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 24 May (5) (2006) 643-656
35. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15 Mar (3) (2009) 293-299
36. Carbonaro D.A., Jin X., Petersen D., Wang X., Dorey F., Kil K.S., et al. In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency. Mol Ther 13 June (6) (2006) 1110-1120
37. Marshall E. Clinical research. Gene therapy a suspect in leukemia-like disease. Science 298 October (5591) (2002) 34-35
38. Wang G.P., Levine B.L., Binder G.K., Berry C.C., Malani N., McGarrity G., et al. Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol Ther 17 Mya (5) (2009) 844-850
39. He Y., and Falo Jr. L.D. Lentivirus as a potent and mechanistically distinct vector for genetic immunization. Curr Opin Mol Ther 9 October (5) (2007) 439-446
40. Radcliffe J.N., Roddick J.S., Stevenson F.K., and Thirdborough S.M. Prolonged antigen expression following DNA vaccination impairs effector CD8+ T cell function and memory development. J Immunol 179 December (12) (2007) 8313-8321
41. Hovav A.H., Panas M.W., Osuna C.E., Cayabyab M.J., Autissier P., and Letvin N.L. The impact of a boosting immunogen on the differentiation of secondary memory CD8+ T cells. J Virol 81 December (23) (2007) 12793-12802
42. Haring J.S., Badovinac V.P., and Harty J.T. Inflaming the CD8+ T cell response. Immunity 25 July (1) (2006) 19-29
43. Lamikanra A., Myers K.A., Ferris N., Mitrophanous K.A., and Carroll M.W. In vivo evaluation of an EIAV vector for the systemic genetic delivery of therapeutic antibodies. Gene Ther 12 June (12) (2005) 988-998